Company intelligence / Profile preview

Da Volterra

Paris, Île-de-France, Francepitchbook.com ↗

Ownership: Private
Employees: ~15
Development stage: Phase 2

Overview

Da Volterra developed DAV132, a product that protects intestinal microbiota from antibiotic-induced disruption. It was tested in four clinical trials with 284 human volunteers and demonstrated proof of concept for protection against antibiotic dysbiosis. The company declared bankruptcy on December 2, 2022.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Live biotherapeutic productsEnzymeAdsorbent technology
Industry: Biotech

Drug pipeline

1 asset

DAV132

Partnerships

European Union Seventh FrameworkBPIFranceEU Innovative Medicines Initiative (IMI)

Beyond the preview

Go deeper on Da Volterra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Da Volterra.

Explore the full profile